Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 118

11 diseases · 22 shared-gene connections
11 Diseases
37 Unique genes
0.150 Avg. similarity score
Chiari-frommel syndrome Most-connected disease (7 links)
Log in to save this analysis

Save This Analysis

Disease Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Chiari-frommel syndrome 7 7 7
Disruptive impulse-control and conduct disorder 6 6 5
Hyperproinsulinemia 6 6 9
Pituitary neoplasms 6 6 6
Dyskinesia, drug-induced 5 5 15
Myoclonic dystonia 4 4 4
Delirium 3 3 10
obsolete early infantile epileptic encephalopathy 3 3 1
Hyperprolactinemia 2 2 1
Bradyopsia 1 1 2
multiple endocrine neoplasia type 4 1 1 1

Top shared genes (genes linked to 2+ member diseases)

Gene ⇵ Member diseases ⇵ Linked diseases
DRD2 7 / 11 Chiari-frommel syndrome, Delirium, Disruptive impulse-control and conduct disorder, Dyskinesia, drug-induced and 3 more
GAD1 4 / 11 Chiari-frommel syndrome, Dyskinesia, drug-induced, Hyperproinsulinemia, obsolete early infantile epileptic encephalopathy
PRL 4 / 11 Chiari-frommel syndrome, Disruptive impulse-control and conduct disorder, Hyperproinsulinemia, Pituitary neoplasms
DRD3 3 / 11 Delirium, Disruptive impulse-control and conduct disorder, Dyskinesia, drug-induced
PRLR 3 / 11 Chiari-frommel syndrome, Hyperproinsulinemia, Hyperprolactinemia
CDKN1B 2 / 11 multiple endocrine neoplasia type 4, Pituitary neoplasms
FOSB 2 / 11 Disruptive impulse-control and conduct disorder, Dyskinesia, drug-induced
GNRH1 2 / 11 Chiari-frommel syndrome, Hyperproinsulinemia
IGF1 2 / 11 Delirium, Pituitary neoplasms
LHB 2 / 11 Chiari-frommel syndrome, Hyperproinsulinemia
PGR 2 / 11 Chiari-frommel syndrome, Hyperproinsulinemia
RGS9 2 / 11 Bradyopsia, Dyskinesia, drug-induced
TH 2 / 11 Delirium, Dyskinesia, drug-induced
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Hormone signaling
DRD2, GNRH1, LHB, PRL, PRLR, DRD3, IGF1, OXTR, CCK, DRD1, PDYN, PENK
 KEGG 15 / 219 22.2× 3.33e-17 1.63e-14 ✓ sig.
Neuroactive ligand-receptor interaction
DRD2, GNRH1, LHB, PRL, PRLR, DRD3, OXTR, CCK, DRD1, PDYN, PENK, AGTR1
 KEGG 13 / 370 11.4× 3.33e-11 5.35e-9 ✓ sig.
Cocaine addiction
RGS9, DRD2, SLC6A3, TH, FOSB, DRD1, PDYN
 KEGG 7 / 49 46.4× 1.13e-10 1.61e-8 ✓ sig.
Dopamine receptors
DRD2, DRD3, DRD1
 Reactome 3 / 5 195× 2.68e-7 1.55e-5 ✓ sig.
Amphetamine addiction
SLC6A3, TH, FOSB, DRD1, PDYN
 KEGG 5 / 69 23.5× 2.04e-6 8.95e-5 ✓ sig.
Prolactin signaling pathway
LHB, PRL, PRLR, TH, INS
 KEGG 5 / 71 22.9× 2.36e-6 1.01e-4 ✓ sig.
FoxO signaling pathway
IGF1, IL6, CAT, HOMER1, INS, CDKN1B
 KEGG 6 / 133 14.6× 2.89e-6 1.20e-4 ✓ sig.
Prolactin receptor signaling
PRL, PRLR, GH1
 Reactome 3 / 12 81.1× 5.81e-6 2.14e-4 ✓ sig.
Growth hormone receptor signaling
PRL, PRLR, GH1
 Reactome 3 / 14 69.6× 9.57e-6 3.24e-4 ✓ sig.
PI3K-Akt signaling pathway
PRL, PRLR, IGF1, IL6, GDNF, INS, CDKN1B, GH1
 KEGG 8 / 361 7.2× 1.11e-5 3.66e-4 ✓ sig.
Interleukin-10 signaling
CXCL8, IL1RN, IL6, LIF
 Reactome 4 / 47 27.6× 1.24e-5 4.00e-4 ✓ sig.
Peptide ligand-binding receptors
CXCL8, CCK, PDYN, PENK, AGTR1
 Reactome 5 / 106 15.3× 1.70e-5 5.22e-4 ✓ sig.
Alcoholism
DRD2, SLC6A3, TH, FOSB, DRD1, PDYN
 KEGG 6 / 188 10.4× 2.11e-5 6.26e-4 ✓ sig.
Synthesis, secretion, and deacylation of Ghrelin
IGF1, INS, GH1
 Reactome 3 / 19 51.3× 2.52e-5 7.21e-4 ✓ sig.
Cytokine-cytokine receptor interaction
PRL, PRLR, CXCL8, IL1RN, IL6, LIF, GH1
 KEGG 7 / 298 7.6× 2.93e-5 8.18e-4 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
response to ethanol
DRD2, GNRH1, DRD3, SLC6A3, TH, FOSB, CAT, PENK
 GO:0045471 8 / 110 36.7× 3.73e-11 1.18e-8 ✓ sig.
regulation of dopamine uptake involved in synaptic transmission
DRD2, DRD3, DRD1, GDNF
 GO:0051584 4 / 5 404× 6.49e-11 1.94e-8 ✓ sig.
behavioral response to cocaine
DRD2, DRD3, FOSB, DRD1, HOMER1
 GO:0048148 5 / 17 149× 1.40e-10 3.89e-8 ✓ sig.
response to cocaine
DRD2, DRD3, SLC6A3, FOSB, DRD1
 GO:0042220 5 / 35 72.2× 7.14e-9 1.28e-6 ✓ sig.
prepulse inhibition
DRD2, DRD3, SLC6A3, DRD1
 GO:0060134 4 / 14 144× 1.28e-8 2.12e-6 ✓ sig.
synaptic transmission, dopaminergic
DRD2, DRD3, TH, DRD1
 GO:0001963 4 / 15 135× 1.75e-8 2.78e-6 ✓ sig.
locomotory behavior
DRD2, DRD3, SLC6A3, TH, DRD1, PENK
 GO:0007626 6 / 99 30.6× 3.86e-8 5.45e-6 ✓ sig.
negative regulation of protein secretion
DRD2, APOE, DRD3, INS
 GO:0050709 4 / 22 91.8× 9.27e-8 1.13e-5 ✓ sig.
positive regulation of MAPK cascade
IGF1, IL6, LIF, DRD1, RASGRF1, INS, GH1
 GO:0043410 7 / 224 15.8× 2.46e-7 2.58e-5 ✓ sig.
hyaloid vascular plexus regression
DRD2, SLC6A3, TH
 GO:1990384 3 / 7 216× 2.49e-7 2.61e-5 ✓ sig.
cell surface receptor signaling pathway via STAT
IGF1, IL6, LIF, GH1
 GO:0097696 4 / 28 72.2× 2.57e-7 2.68e-5 ✓ sig.
response to amphetamine
RGS9, DRD2, FOSB, DRD1
 GO:0001975 4 / 31 65.2× 3.94e-7 3.83e-5 ✓ sig.
phospholipase C-activating dopamine receptor signaling pathway
DRD2, DRD3, DRD1
 GO:0060158 3 / 8 189× 3.97e-7 3.85e-5 ✓ sig.
dopamine biosynthetic process
SLC6A3, TH, GCH1
 GO:0042416 3 / 9 168× 5.95e-7 5.42e-5 ✓ sig.
G protein-coupled dopamine receptor signaling pathway
RGS9, DRD2, DRD1
 GO:0007212 3 / 9 168× 5.95e-7 5.42e-5 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
Chiari-frommel syndrome Hyperproinsulinemia 0.700 7 8.85e-25 2.27e-23 ✓ sig.
Disruptive impulse-control and conduct disorder Dyskinesia, drug-induced 0.167 3 7.47e-9 6.56e-8 ✓ sig.
Delirium Dyskinesia, drug-induced 0.130 3 8.94e-8 6.63e-7 ✓ sig.
Disruptive impulse-control and conduct disorder Pituitary neoplasms 0.200 2 1.26e-6 7.70e-6 ✓ sig.
Chiari-frommel syndrome Disruptive impulse-control and conduct disorder 0.182 2 1.77e-6 1.05e-5 ✓ sig.
Chiari-frommel syndrome Pituitary neoplasms 0.167 2 2.65e-6 1.53e-5 ✓ sig.
Disruptive impulse-control and conduct disorder Hyperproinsulinemia 0.154 2 3.03e-6 1.72e-5 ✓ sig.
Delirium Disruptive impulse-control and conduct disorder 0.143 2 3.79e-6 2.12e-5 ✓ sig.
Hyperproinsulinemia Pituitary neoplasms 0.143 2 4.55e-6 2.52e-5 ✓ sig.
Delirium Pituitary neoplasms 0.133 2 5.69e-6 3.09e-5 ✓ sig.
Chiari-frommel syndrome Dyskinesia, drug-induced 0.095 2 1.85e-5 9.34e-5 ✓ sig.
multiple endocrine neoplasia type 4 Pituitary neoplasms 0.143 1 3.90e-4 8.52e-4 ✓ sig.
Chiari-frommel syndrome obsolete early infantile epileptic encephalopathy 0.125 1 4.55e-4 9.55e-4 ✓ sig.
Chiari-frommel syndrome Hyperprolactinemia 0.125 1 4.55e-4 9.55e-4 ✓ sig.
Hyperproinsulinemia Hyperprolactinemia 0.100 1 5.84e-4 1.14e-3 ✓ sig.
Hyperproinsulinemia obsolete early infantile epileptic encephalopathy 0.100 1 5.84e-4 1.14e-3 ✓ sig.
Dyskinesia, drug-induced obsolete early infantile epileptic encephalopathy 0.063 1 9.74e-4 1.64e-3 ✓ sig.
Disruptive impulse-control and conduct disorder Myoclonic dystonia 0.111 1 1.30e-3 2.04e-3 ✓ sig.
Myoclonic dystonia Pituitary neoplasms 0.100 1 1.56e-3 2.36e-3 ✓ sig.
Chiari-frommel syndrome Myoclonic dystonia 0.091 1 1.82e-3 2.66e-3 ✓ sig.
Bradyopsia Dyskinesia, drug-induced 0.059 1 1.95e-3 2.81e-3 ✓ sig.
Hyperproinsulinemia Myoclonic dystonia 0.077 1 2.34e-3 3.23e-3 ✓ sig.